Indefinite Delivery Contract HHSD200201562100I

This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC as the prime contractor. The contract, valued at up to $1.25 billion, is part of the Vaccines for Children (VFC) 2015 program and provides for the delivery of various vaccines and pharmaceutical products to support federal immunization and disease prevention initiatives.

Key products and services included under this multiple award IDV contract include seasonal influenza vaccines, pediatric and adult vaccines for routine immunization programs, and antiviral medications such as zanamivir. The contract also allows for the provision of vaccine storage and rotation services, as well as the supply of COVID-19 treatments and vaccine adjuvants. Performance will primarily occur at Glaxosmithkline's facilities in North Carolina, with no set-aside designations indicated. The 5-year contract period runs from April 2015 through March 2020, with specific quantities and delivery timelines determined through task orders placed by the CDC based on public health needs. This contract supports the CDC's efforts to ensure adequate stockpiles and distribution of critical vaccines and antivirals for federal, state, and local immunization programs.